LEIDEN, The Netherlands & SEATTLE--(BUSINESS WIRE)--ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), will present the results of the company’s Fibrocaps Phase II (FC-002) trial, as well as the progress made by ProFibrix in its groundbreaking recombinant fibrinogen program at two international scientific conferences this week.
|10th World Congress of the International Hepato-Pancreato-Biliary Association, July 1-5, Palais des Congres, Paris, France|
Fibrocaps™, A Novel Fibrin Sealant, for Bleeding During Hepatic Resection: Results of a Phase 2, Randomized, Controlled Study
|Presenter: Cornelis Verhoef MD, PhD, Division of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Center, the Netherlands|
|Date: July 5, 2012|
|Presentation Time: 8:45 – 10:30; Location: Room 253|
|XXIInd International Fibrinogen Workshop, the Biennial Meeting of the International Society on Fibrinogen Research (IFRS), 4-6 July, Thistle Hotel, Brighton, UK|
Recombinant Human Fibrinogen: Production and Characterization
|Presenter: Jos Grimbergen, Bsc . Director R&D, ProFibrix BV, Leiden, the Netherlands|
|Date: July 5, 2012|
|Presentation Time: 16:45 – 17:45; Location: Renaissance Ballroom|
Fibrocaps is a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical fibrin sealant being developed to stop bleeding during or after surgery. Fibrocaps is clearly differentiated from existing liquid tissue sealants and hemostats: it is ready for immediate use, and is stable at room temperature.
About recombinant fibrinogen
The only currently available source of human fibrinogen is plasma from human donor blood. Experts believe that in the future there will be a shortage of safe plasma-derived fibrinogen. ProFibrix is developing a commercially feasible recombinant production platform for human fibrinogen to enable the development of new, advanced products. The recombinant fibrinogen platform in development will provide ProFibrix with a unique position in the hemostasis and tissue repair market. The first indication for recombinant fibrinogen may be systemic therapy for patients with inadequate levels of circulating functional fibrinogen.
ProFibrix (www.profibrix.com) was founded in 2004 and is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA, USA. The company leverages its expertise in fibrinogen technology to develop and bring to market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field.